2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 883

Evaluation of Fracture Risk and Osteoporosis in Males with Rheumatoid Arthritis
Abstract Number: 2215

Evaluation of Left Ventricular Systolic and Diastolic Myocardial Function in Patients with Ankylosing Spondylitis By Speckle-Tracking Echocardiography
Abstract Number: 2712

Evaluation of Longitudinal Outcomes in Scleroderma Patients with Negative Immunofluorescent Anti-Nuclear Antibodies
Abstract Number: 591

Evaluation of MRI Ramris Score and Clinical Response in Patients with ACPA Positive Undifferentiated Arthritis Treated with Infliximab Versus Placebo
Abstract Number: 2960

Evaluation of Performance Measures Reveals Delays and Sub-Optimal Access to Rheumatology Care and Treatment
Abstract Number: 1323

Evaluation of Prolidase and HIF-1α Levels in Patients with Familial Mediterranean Fever (FMF)
Abstract Number: 189

Evaluation of Rheumatology Lectures By Clinical Students in a Nigerian Medical School: Learning from the Learners
Abstract Number: 1761

Evaluation of the Functional Activity of Endothelial Progenitor Cells in Patients with ANCA-Associated Vasculitis
Abstract Number: 1584

Evaluation of the Performance of the 2016 American College of Rheumatology-European League Against Rheumatism (Acr-Eular) Classification Criteria for Primary Sjogren`S Syndrome in Different Centers of Argentina
Abstract Number: 478

Evidence Based Recommendations for Corticosteroid Tapering/Discontinuation in New Onset Juvenile Dermatomyositis Patients: Results from the Paediatric Rheumatology International Trials Organisation
Abstract Number: 112

Evidence for Altered Peroxisome Proliferator Activated Receptor (PPAR) Pathway Activity in a Transgenic Mouse Model of Scleroderma (TβRIIΔk-fib): Analysis of Mouse Skin, Lung and Explanted Cells
Abstract Number: 937

Evidence of a Common Microglial Signature in Models of ‘Neuropsychiatric Symptoms of Systemic Lupus Erythematosus’
Abstract Number: 2022

Evidence of Inflammation Amplification By Interleukin-6 and Interleukin-17A in Synovial Compartment of Juvenile Idiopathic Arthritis – Enthesitis Related Arthritis
Abstract Number: 2602

Evolution of Patient Characteristics in the Era of Biological Treatment of Psoriatic Arthritis: 18-Year Belgian Experience from Leuven Spondyloarthritis Biologics Cohort (BioSPAR)
Abstract Number: 2914

Examination of Psychometric Properties of the Patient-Reported Outcomes Measurement Information System Fatigue 4-Item Short Form in Psoriatic Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].